Business

Advicenne: 2026 Financial Calendar

PARIS, January 20, 2026--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2026 financial communication calendar.

articleAdvicenne SaJanuary 20, 20261/company/advicenne-sa/news/advicenne-2026-financial-calendar-1
Advicenne: 2026 Financial Calendar

About this update from Advicenne Sa

[{"type":"text","content":"PARIS, January 20, 2026--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2026 financial communication calendar.","length":265,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-top:solid black 1.0pt;border-bottom:solid black 1.0pt;padding-left:0.0px;width:60%;","val":[{"type":"text","content":"Event","length":5,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-top:solid black 1.0pt;border-bottom:solid black 1.0pt;padding-left:0.0px;width:40%;","val":[{"type":"text","content":"Date*","length":5,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-bottom:solid black 1.0pt;padding-left:0.0px;width:60%;","val":[{"type":"text","content":"2025 FY sales release","length":21,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-bottom:solid black 1.0pt;padding-left:0.0px;width:40%;","val":[{"type":"text","content":"January 22, 2026","length":16,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-bottom:solid black 1.0pt;padding-left:0.0px;width:60%;","val":[{"type":"text","content":"2025 FY annual financial statement","length":34,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-bottom:solid black 1.0pt;padding-left:0.0px;width:40%;","val":[{"type":"text","content":"March 26, 2026","length":14,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-bottom:solid black 1.0pt;padding-left:0.0px;width:60%;","val":[{"type":"text","content":"Annual General Meeting","length":22,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-bottom:solid black 1.0pt;padding-left:0.0px;width:40%;","val":[{"type":"text","content":"May 21, 2026","length":12,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"vertical-align:top;border-bottom:solid black 1.0pt;padding-left:0.0px;wid...

More updates from Advicenne Sa

pharmaceutical companyEuronext Parisrenal diseasesRegulatory News